255 related articles for article (PubMed ID: 18763027)
1. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial.
Caproni M; Antiga E; Melani L; Volpi W; Del Bianco E; Fabbri P
J Clin Immunol; 2009 Mar; 29(2):210-4. PubMed ID: 18763027
[TBL] [Abstract][Full Text] [Related]
2. Palmoplantar pustulosis with arthro-osteitis: successful treatment with etanercept and acitretin.
Antoniou C; Nicolaidou E; Moustou AE; Stratigos A; Katsambas A
J Eur Acad Dermatol Venereol; 2009 Jul; 23(7):854-5. PubMed ID: 19646137
[No Abstract] [Full Text] [Related]
3. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
[TBL] [Abstract][Full Text] [Related]
4. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.
Antiga E; Volpi W; Cardilicchia E; Maggi L; Filì L; Manuelli C; Parronchi P; Fabbri P; Caproni M
J Clin Immunol; 2012 Dec; 32(6):1221-32. PubMed ID: 22699761
[TBL] [Abstract][Full Text] [Related]
5. The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris.
Antiga E; Volpi W; Chiarini C; Cardilicchia E; Filì L; Manuelli C; Parrochi P; Fabbri P; Caproni M
Int J Immunopathol Pharmacol; 2010; 23(3):767-74. PubMed ID: 20943046
[TBL] [Abstract][Full Text] [Related]
6. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
7. Etanercept for the treatment of psoriasis: combination therapy with other modalities.
Strober BE; Clarke S
J Drugs Dermatol; 2004; 3(3):270-2. PubMed ID: 15176161
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with acitretin for psoriasis.
Hodulik SG; Zeichner JA
J Dermatolog Treat; 2006; 17(2):108-11. PubMed ID: 16766335
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of interleukin-2 and tumour necrosis factor-α under cyclosporine versus acitretin treatment in plaque-type psoriasis.
Akçali C; Guven EH; Kirtak N; Inaloz HS; Ozgoztasi O; Guvenc U
J Int Med Res; 2014 Oct; 42(5):1118-22. PubMed ID: 25143337
[TBL] [Abstract][Full Text] [Related]
10. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
11. Etanercept and recalcitrant acrodermatitis continua of Hallopeau.
Nikkels AF; Piérard GE
J Drugs Dermatol; 2006 Sep; 5(8):705-6. PubMed ID: 16991229
[No Abstract] [Full Text] [Related]
12. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
13. Novel combination regimens: biologics and acitretin for the treatment of psoriasis-- a case series.
Conley J; Nanton J; Dhawan S; Pearce DJ; Feldman SR
J Dermatolog Treat; 2006; 17(2):86-9. PubMed ID: 16766332
[TBL] [Abstract][Full Text] [Related]
14. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
15. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.
Cassano N; Loconsole F; Miracapillo A; Travaglini M; Digiuseppe MD; Congedo M; Galluccio A; Buquicchio R; Mastrandrea V; Filieri M; Raho G; Pezza M; Vena GA
Int J Immunopathol Pharmacol; 2010; 23(3):797-802. PubMed ID: 20943050
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.
Yeung H; Wan J; Van Voorhees AS; Callis Duffin K; Krueger GG; Kalb RE; Weisman JD; Sperber BR; Brod BA; Schleicher SM; Bebo BF; Shin DB; Troxel AB; Gelfand JM
J Am Acad Dermatol; 2013 Jan; 68(1):64-72. PubMed ID: 22846688
[TBL] [Abstract][Full Text] [Related]
19. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
20. Failure of combination therapy with acitretin and cyclosporin A in 3 patients with erythrodermic psoriasis.
Kuijpers AL; van Dooren-Greebe JV; van de Kerkhof PC
Dermatology; 1997; 194(1):88-90. PubMed ID: 9031805
[No Abstract] [Full Text] [Related]
[Next] [New Search]
